October 1, 2022 - Volume 91 - Issue S1 : JAIDS Journal of Acquired Immune Deficiency Syndromes

Secondary Logo

Journal Logo

October 1, 2022 - Volume 91 - S1
pp: S1-S50

Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study

Tongtong, Yang; Shenghua, He; Yin, Wang; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(S1):S1-S7, October 1, 2022.

Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China

Sun, Liqin; He, Yun; Xu, Liumei; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(S1):S8-S15, October 1, 2022.

Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Observational Study

Yan, Dongmei; Wang, Zongzheng; Wang, Yan; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(S1):S35-S41, October 1, 2022.

Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1–Infected Patients: A Multicenter Cohort Study in China

Zhong, Mingli; Chen, Chen; Hu, Yue; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(S1):S42-S50, October 1, 2022.